At a glance
ClinicalIndex Comparison RecordN/ACompleted· 59 enrolled
Drug / intervention
COVID-19 Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COVID-19 Vaccine Response in People Living With Sickle Cell Disease
In Brief
An observational study evaluating COVID-19 Vaccine for Sickle Cell Disease and COVID-19. Completed, enrolled 59 participants across 8 sites.
Detailed Summary
The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease, COVID-19
CountriesUnited States
CollaboratorsAmerican Society of Hematology, University of Pennsylvania
Timeline
N/ACompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartDec 2021
Primary CompletionDec 2023
TodayJul 2026
First PostedDec 1, 2021
Enrollment StartDec 1, 2021
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.6 years ago
Interventions
COVID-19 Vaccinebiological
Vaccination against SARS-CoV-2 administered as part of standard of care